Constellation Pharmaceuticals Inc (NASDAQ:CNST) – Investment analysts at Jefferies Financial Group issued their Q3 2018 EPS estimates for Constellation Pharmaceuticals in a research note issued on Monday, August 13th. Jefferies Financial Group analyst M. Raycroft forecasts that the company will earn ($0.81) per share for the quarter. Jefferies Financial Group also issued estimates for Constellation Pharmaceuticals’ Q4 2018 earnings at ($0.89) EPS, FY2018 earnings at ($2.64) EPS, FY2019 earnings at ($2.52) EPS, FY2020 earnings at ($3.24) EPS, FY2021 earnings at ($0.79) EPS and FY2022 earnings at ($4.61) EPS.
Constellation Pharmaceuticals (NASDAQ:CNST) last posted its quarterly earnings results on Tuesday, August 14th. The company reported ($9.96) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($9.25).
CNST stock opened at $10.61 on Thursday. Constellation Pharmaceuticals has a 12-month low of $9.00 and a 12-month high of $12.21.
In related news, Director Anthony B. Evnin acquired 133,334 shares of Constellation Pharmaceuticals stock in a transaction on Monday, July 23rd. The shares were bought at an average price of $15.00 per share, for a total transaction of $2,000,010.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider James E. Flynn acquired 200,000 shares of Constellation Pharmaceuticals stock in a transaction on Monday, July 23rd. The shares were bought at an average price of $15.00 per share, for a total transaction of $3,000,000.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 400,001 shares of company stock worth $6,000,015.
About Constellation Pharmaceuticals
There is no company description available for Constellation Pharmaceuticals Inc
Featured Article: NASDAQ Stock Market Explained
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.